Pharmacology Quiz: Antifungal Antiparasitic Toxicity
20 questions · exam conditions
0:00
Antifungal Antiparasitic ToxicityQuestion 1 of 20

A patient being treated with oral metronidazole for trichomoniasis consumes an alcoholic beverage. Shortly thereafter, she experiences facial flushing, throbbing headache, nausea, and tachycardia. This reaction results from the inhibition of aldehyde dehydrogenase, leading to the accumulation of what substance?

Methanol
Lactic acid
Ethanol
Acetaldehyde
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Antifungal Antiparasitic Toxicity

Practice Antifungal Antiparasitic Toxicity in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Antifungal Antiparasitic Toxicity, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient being treated with oral metronidazole for trichomoniasis consumes an alcoholic beverage. Shortly thereafter, she experiences facial flushing, throbbing headache, nausea, and tachycardia. This reaction results from the inhibition of aldehyde dehydrogenase, leading to the accumulation of what substance?

  1. Methanol
  2. Lactic acid
  3. Ethanol
  4. Acetaldehyde (correct answer)
Explanation: Metronidazole can cause a disulfiram-like reaction when taken with alcohol. This occurs because the drug inhibits the enzyme aldehyde dehydrogenase, which is responsible for metabolizing acetaldehyde (a toxic intermediate of alcohol metabolism) into acetate. The resulting buildup of acetaldehyde causes the characteristic symptoms of flushing, nausea, vomiting, and tachycardia. Ethanol is the parent compound, while lactic acid and methanol are not involved in this specific reaction.

Question 2

A patient being treated with oral metronidazole for trichomoniasis consumes an alcoholic beverage. Shortly thereafter, she experiences facial flushing, throbbing headache, nausea, and tachycardia. This reaction results from the inhibition of aldehyde dehydrogenase, leading to the accumulation of what substance?

  1. Methanol
  2. Lactic acid
  3. Ethanol
  4. Acetaldehyde (correct answer)
Explanation: Metronidazole can cause a disulfiram-like reaction when taken with alcohol. This occurs because the drug inhibits the enzyme aldehyde dehydrogenase, which is responsible for metabolizing acetaldehyde (a toxic intermediate of alcohol metabolism) into acetate. The resulting buildup of acetaldehyde causes the characteristic symptoms of flushing, nausea, vomiting, and tachycardia. Ethanol is the parent compound, while lactic acid and methanol are not involved in this specific reaction.

Question 3

A patient with neurocysticercosis is prescribed a 30-day course of high-dose albendazole. Which of the following laboratory parameters should be monitored most closely during this extended, high-dose therapy?

  1. Serum creatinine and electrolytes
  2. Thyroid stimulating hormone and free T4
  3. Liver aminotransferases and complete blood count (correct answer)
  4. Electrocardiogram and serum magnesium
Explanation: While albendazole is generally well-tolerated in short courses for intestinal parasites, high-dose and long-term therapy (e.g., for hydatid disease or neurocysticercosis) is associated with more significant toxicities. The primary concerns are hepatotoxicity (elevated liver enzymes) and bone marrow suppression (leukopenia, pancytopenia). Therefore, frequent monitoring of liver function tests and a complete blood count is essential during treatment.

Question 4

A patient from a rural area in West Africa is diagnosed with onchocerciasis and treated with ivermectin. Several hours after the dose, he develops fever, pruritus, diffuse rash, and mild hypotension. This constellation of symptoms, known as the Mazzotti reaction, is primarily caused by which mechanism?

  1. A systemic inflammatory response to antigens released from dying microfilariae. (correct answer)
  2. Direct drug-induced mast cell degranulation leading to histamine release.
  3. An IgE-mediated anaphylactic reaction to the ivermectin tablet excipients.
  4. Acute neurotoxicity resulting from ivermectin crossing the blood-brain barrier.
Explanation: When you encounter questions about drug reactions in tropical disease treatment, consider whether symptoms arise from the drug itself or from the pathophysiological response to parasite death. The Mazzotti reaction is a well-documented inflammatory response that occurs when ivermectin kills Onchocerca volvulus microfilariae. As these parasites die, they release intracellular contents including proteins, enzymes, and other antigenic material into surrounding tissues and circulation. The host's immune system recognizes these foreign antigens and mounts an inflammatory response, leading to fever, skin reactions, and mild hypotension. This explains why the reaction occurs hours after treatment—it takes time for sufficient microfilarial death and antigen release to trigger the inflammatory cascade. Option A correctly identifies this mechanism: systemic inflammation from antigens released by dying microfilariae. Option B is incorrect because this isn't direct mast cell degranulation from ivermectin itself, but rather an immune response to parasite antigens. Option C describes a true drug allergy to ivermectin components, which would typically occur more rapidly and present with different symptoms. Option D is wrong because ivermectin doesn't readily cross the blood-brain barrier in humans at therapeutic doses, and neurotoxicity wouldn't explain the specific constellation of inflammatory symptoms described. Remember that antiparasitic drug reactions often stem from parasite death rather than direct drug toxicity. The Mazzotti reaction is paradoxically a sign that the treatment is working—the more parasites killed, the more intense the reaction may be.

Question 5

A patient with acute myeloid leukemia is receiving posaconazole oral suspension for prophylaxis of invasive fungal infections. A routine therapeutic drug monitoring level returns at 0.4 mcg/mL (prophylactic goal >0.7 mcg/mL), despite the patient's reported adherence. This subtherapeutic concentration is most likely attributable to which factor?

  1. Erratic and poor gastrointestinal absorption, which is dependent on food intake. (correct answer)
  2. Saturation of plasma protein binding sites, leading to rapid drug clearance.
  3. Induction of posaconazole metabolism by a concurrently administered chemotherapy agent.
  4. Formation of an inactive metabolite that cross-reacts poorly with the laboratory assay.
Explanation: When you encounter subtherapeutic drug levels despite reported adherence, consider the pharmacokinetic factors that could impair drug exposure, particularly absorption for oral medications. Posaconazole oral suspension has notoriously erratic and variable gastrointestinal absorption that is highly dependent on food intake and gastric pH. The drug requires an acidic environment and fatty food to achieve adequate bioavailability. In patients with acute myeloid leukemia, factors like mucositis from chemotherapy, nausea, vomiting, and poor oral intake significantly compromise absorption. Even with perfect adherence to dosing, these gastrointestinal factors can lead to subtherapeutic levels, making option A correct. Option B is incorrect because posaconazole has high protein binding (>98%), but saturation of binding sites would actually increase free drug levels, not decrease total measurable concentrations. Option C misrepresents posaconazole's metabolism - it's primarily eliminated unchanged via feces, and hepatic metabolism is minimal, so CYP induction wouldn't significantly impact levels. Option D is wrong because posaconazole undergoes minimal metabolism to inactive metabolites, and modern assays are specific for the parent compound. Study tip: For azole antifungals, remember the "3 A's" that affect levels: Absorption (especially posaconazole suspension), Acid suppression (reduces absorption), and Adherence. When you see subtherapeutic azole levels, always consider gastrointestinal factors first, particularly with posaconazole suspension, which has the most problematic absorption profile among the azoles.

Question 6

A patient with rhinocerebral mucormycosis requires high-dose amphotericin B. To minimize nephrotoxicity, a lipid formulation is chosen. When comparing liposomal amphotericin B (L-AMB) and amphotericin B lipid complex (ABLC), which statement accurately describes a known difference in their common toxicity profiles?

  1. L-AMB is associated with a significantly higher incidence of infusion-related reactions than ABLC.
  2. ABLC is associated with a higher incidence of infusion-related reactions (chills, fever) than L-AMB. (correct answer)
  3. L-AMB is known to cause more severe hypokalemia and hypomagnesemia than ABLC.
  4. ABLC has a substantially higher rate of nephrotoxicity compared to L-AMB at equivalent doses.
Explanation: While all lipid formulations of amphotericin B are less nephrotoxic than the conventional form, there are subtle differences in their other side effects. Comparative studies and clinical experience have shown that amphotericin B lipid complex (ABLC) is associated with a higher rate of infusion-related reactions (fever, chills, rigors) compared to liposomal amphotericin B (L-AMB). Both are considered less nephrotoxic than conventional amphotericin B, with L-AMB often regarded as the least nephrotoxic of all formulations.

Question 7

A 59-year-old woman with cryptococcal meningitis is scheduled to receive conventional amphotericin B deoxycholate. Her baseline serum creatinine is 1.1 mg/dL. The clinical team wishes to implement a strategy with the greatest efficacy for preventing amphotericin B-induced nephrotoxicity. Which intervention should be prioritized?

  1. Administering a 1 mg test dose over 20 minutes before the first full dose.
  2. Premedicating with acetaminophen and diphenhydramine 30 minutes prior to each infusion.
  3. Administering 500 to 1000 mL of 0.9% sodium chloride intravenously before each dose. (correct answer)
  4. Initiating daily oral potassium and magnesium supplementation at the start of therapy.
Explanation: The most effective prophylactic measure to mitigate the nephrotoxicity of conventional amphotericin B is pre-infusion hydration with normal saline. This practice, known as saline loading, is thought to prevent the afferent arteriolar vasoconstriction that contributes to the drug's renal toxicity. Administering a test dose and premedicating with antipyretics/antihistamines are strategies to manage infusion-related reactions (fever, chills), not nephrotoxicity. Supplementing electrolytes treats the consequences of renal tubular damage but does not prevent the initial injury.

Question 8

A 35-year-old lung transplant recipient on long-term prophylactic voriconazole develops an erythematous, scaling rash on sun-exposed areas. In addition to counseling on sun avoidance, the patient should be informed that this chronic phototoxicity is associated with an increased long-term risk of which of the following?

  1. Malignant melanoma
  2. Drug-induced lupus erythematosus
  3. Squamous cell carcinoma (correct answer)
  4. Acute generalized exanthematous pustulosis
Explanation: Long-term voriconazole use is associated with chronic photosensitivity, which can lead to accelerated photo-aging and an increased risk of cutaneous malignancies, most notably squamous cell carcinoma (SCC). The mechanism is thought to involve the accumulation of a phototoxic metabolite in the skin. This risk is particularly high in immunocompromised patients, such as solid organ transplant recipients. While other skin conditions can occur, the link between voriconazole phototoxicity and SCC is well-established and a primary long-term concern.

Question 9

A 50-year-old patient is prescribed a 12-week course of oral terbinafine for onychomycosis. Which of the following counseling points is most critical to convey to the patient regarding a rare but potentially life-threatening adverse effect?

  1. Report any unusual taste disturbances, as this may be an early sign of neurotoxicity.
  2. Stop the medication and seek immediate medical attention for symptoms like fatigue, dark urine, or jaundice. (correct answer)
  3. Avoid direct sunlight and use sunscreen, as the medication can increase photosensitivity.
  4. Take the medication with food to minimize gastrointestinal upset and improve absorption.
Explanation: Oral terbinafine is associated with a rare risk of idiosyncratic, severe, and sometimes fatal hepatotoxicity. Patients must be counseled to recognize the signs and symptoms of liver injury (e.g., persistent nausea, anorexia, fatigue, jaundice, dark urine, pale stools) and to stop the drug and seek immediate medical care if they occur. While taste disturbance is a known side effect, it is not life-threatening. Photosensitivity is not a major concern with terbinafine, and taking it with food is a general recommendation, not a critical safety issue.

Question 10

A 62-year-old renal transplant recipient with a creatinine clearance of 35 mL/min is being treated with amphotericin B and flucytosine for cryptococcal meningitis. On day 7 of therapy, his WBC count drops to 1.5 x 10³/µL and platelet count to 50 x 10³/µL. This hematologic toxicity is most directly caused by the accumulation of which substance?

  1. 5-Fluorouracil, a metabolite of flucytosine. (correct answer)
  2. Flucytosine, due to direct inhibition of host cell thymidylate synthetase.
  3. Amphotericin B, due to suppression of erythropoietin production.
  4. Unmetabolized flucytosine, which directly suppresses bone marrow precursors.
Explanation: Flucytosine (5-FC) is converted to the cytotoxic antimetabolite 5-fluorouracil (5-FU) by cytosine deaminase, an enzyme present in fungi and some gut bacteria. Humans lack this enzyme in most cells, which provides a degree of selectivity. However, some conversion occurs, and 5-FU is responsible for the dose-limiting bone marrow suppression (leukopenia, thrombocytopenia). Since flucytosine is renally cleared, patients with renal impairment are at high risk for drug accumulation and subsequent increased conversion to toxic 5-FU levels.

Question 11

A patient with HIV and a sulfa allergy is receiving intravenous pentamidine for Pneumocystis jirovecii pneumonia. On day 5, his blood glucose is 45 mg/dL. What is the mechanism for this adverse effect, and what subsequent metabolic complication should be anticipated?

  1. Increased peripheral insulin sensitivity, which may be followed by rebound hyperglycemia.
  2. Direct pancreatic β-cell lysis causing acute insulin release, potentially followed by hyperglycemia or diabetes. (correct answer)
  3. Inhibition of hepatic gluconeogenesis, which resolves completely upon drug cessation.
  4. Competitive inhibition of glucagon secretion, leading to persistent hypoglycemia throughout therapy.
Explanation: Pentamidine is directly toxic to pancreatic β-cells. Initially, this cytotoxicity can cause the cells to lyse and release large amounts of stored insulin, leading to profound and sudden hypoglycemia. If the damage is extensive, the patient may subsequently develop insulin-dependent diabetes mellitus due to the destruction of insulin-producing cells. This biphasic effect (hypoglycemia followed by potential hyperglycemia) is a unique and dangerous toxicity of pentamidine.

Question 12

A 48-year-old patient with a creatinine clearance of 25 mL/min is being treated for invasive aspergillosis with intravenous voriconazole. Which of the following adverse effects is specifically related to the accumulation of the intravenous formulation's vehicle in this patient population?

  1. Visual disturbances, including photopsia and color changes.
  2. Worsening renal function and potential neurotoxicity. (correct answer)
  3. QTc interval prolongation on electrocardiogram.
  4. Development of a photosensitivity-related dermatitis.
Explanation: The intravenous formulation of voriconazole contains a cyclodextrin vehicle (sulfobutylether-β-cyclodextrin sodium, or SBECD) to enhance solubility. SBECD is eliminated by the kidneys and can accumulate in patients with moderate to severe renal impairment (CrCl < 50 mL/min). This accumulation has been linked to nephrotoxicity and neurotoxicity, independent of voriconazole itself. Therefore, the oral formulation is preferred in these patients. Visual disturbances, QTc prolongation, and photosensitivity are known toxicities of the voriconazole molecule itself, not the IV vehicle.

Question 13

A 28-year-old patient receives a full course of intravenous artesunate for severe Plasmodium falciparum malaria and is discharged after clinical improvement. Which of the following represents the most important monitoring that should be conducted in the weeks following discharge?

  1. Weekly electrocardiograms to monitor for delayed cardiotoxicity.
  2. Neuropsychiatric assessment to screen for psychosis or vivid dreams.
  3. Weekly complete blood counts to monitor for delayed hemolysis. (correct answer)
  4. Monthly liver function tests to monitor for drug-induced hepatitis.
Explanation: Intravenous artesunate, a cornerstone for treating severe malaria, is associated with post-treatment delayed hemolytic anemia. This phenomenon typically occurs 1-3 weeks after completion of therapy and involves the clearance of once-infected erythrocytes that have been 'pitted' of their parasites by the spleen. Monitoring hemoglobin/hematocrit via weekly CBCs for up to 4 weeks post-treatment is recommended. The other options are toxicities more characteristic of other antimalarials (e.g., neuropsychiatric effects with mefloquine).

Question 14

A 34-year-old traveler returning from a region endemic for Plasmodium vivax is diagnosed with malaria. After an initial course of treatment for the acute infection, the physician plans to add primaquine for radical cure to prevent relapse. Which of the following is the most critical screening test to perform before initiating primaquine therapy?

  1. Baseline electrocardiogram (ECG) for QTc interval assessment.
  2. Glucose-6-phosphate dehydrogenase (G6PD) activity assay. (correct answer)
  3. Comprehensive ophthalmologic examination, including visual fields.
  4. Serum liver function tests (LFTs), including bilirubin and transaminases.
Explanation: Primaquine can induce severe, life-threatening acute hemolytic anemia in individuals with a G6PD deficiency. Therefore, screening for G6PD activity is mandatory before initiating therapy. While other monitoring (ECG for other antimalarials, LFTs) may be relevant, the risk of hemolysis in a G6PD-deficient patient is the most acute and severe toxicity associated with primaquine, making this screening test the most critical.

Question 15

A 22-year-old student is seeking malaria prophylaxis for a trip to sub-Saharan Africa. Her medical history is significant for an anxiety disorder and a past episode of depression. Which antimalarial agent is generally contraindicated due to a black box warning for severe, potentially permanent, neuropsychiatric adverse effects?

  1. Atovaquone-proguanil
  2. Doxycycline
  3. Chloroquine
  4. Mefloquine (correct answer)
Explanation: Mefloquine carries a black box warning from the FDA regarding the risk of serious and potentially permanent neuropsychiatric adverse reactions, including anxiety, paranoia, depression, hallucinations, and suicidal ideation. Due to this risk, it is contraindicated in patients with a current or recent history of major psychiatric disorders such as depression, anxiety disorders, psychosis, or schizophrenia.

Question 16

A 45-year-old female has been taking hydroxychloroquine 400 mg daily for 6 years for rheumatoid arthritis. Given the cumulative dose and duration of therapy, monitoring for which of the following toxicities is most critical to prevent irreversible end-organ damage?

  1. Cardiomyopathy via annual echocardiogram.
  2. Retinopathy via annual comprehensive ophthalmologic examination. (correct answer)
  3. Myelosuppression via quarterly complete blood count.
  4. Nephrotoxicity via semi-annual serum creatinine measurement.
Explanation: The most significant, dose- and duration-dependent toxicity of long-term hydroxychloroquine use is irreversible retinopathy, which can progress even after drug discontinuation. Guidelines recommend a baseline ophthalmologic exam and annual screening after 5 years of use (or sooner with major risk factors). Screening includes visual field testing and spectral-domain optical coherence tomography (SD-OCT). While other toxicities like cardiomyopathy can occur, they are much rarer, and retinal toxicity is the primary focus of long-term monitoring to prevent permanent vision loss.

Question 17

A 45-year-old patient with invasive candidiasis is receiving caspofungin 50 mg daily. His medical history is significant for tuberculosis, for which he is being treated with a regimen that includes rifampin. What adjustment to the caspofungin regimen is warranted?

  1. No dose adjustment is necessary as there is no interaction.
  2. Decrease the caspofungin maintenance dose to 35 mg daily.
  3. Increase the caspofungin maintenance dose to 70 mg daily. (correct answer)
  4. Administer caspofungin and rifampin at least 4 hours apart.
Explanation: Rifampin is a potent inducer of drug-metabolizing enzymes and has been shown to induce the clearance of caspofungin, potentially leading to subtherapeutic concentrations. When co-administering caspofungin with rifampin, it is recommended to increase the daily maintenance dose of caspofungin from 50 mg to 70 mg in adults to ensure adequate drug exposure and efficacy. Decreasing the dose would be incorrect, and separating administration times does not mitigate an induction interaction.

Question 18

A 48-year-old patient with a creatinine clearance of 25 mL/min is being treated for invasive aspergillosis with intravenous voriconazole. Which of the following adverse effects is specifically related to the accumulation of the intravenous formulation's vehicle in this patient population?

  1. Visual disturbances, including photopsia and color changes.
  2. Worsening renal function and potential neurotoxicity. (correct answer)
  3. QTc interval prolongation on electrocardiogram.
  4. Development of a photosensitivity-related dermatitis.
Explanation: The intravenous formulation of voriconazole contains a cyclodextrin vehicle (sulfobutylether-β-cyclodextrin sodium, or SBECD) to enhance solubility. SBECD is eliminated by the kidneys and can accumulate in patients with moderate to severe renal impairment (CrCl < 50 mL/min). This accumulation has been linked to nephrotoxicity and neurotoxicity, independent of voriconazole itself. Therefore, the oral formulation is preferred in these patients. Visual disturbances, QTc prolongation, and photosensitivity are known toxicities of the voriconazole molecule itself, not the IV vehicle.

Question 19

A 55-year-old heart transplant recipient, maintained on tacrolimus, develops invasive aspergillosis and is started on voriconazole. Three days later, he presents with tremor, headache, and a serum creatinine of 2.5 mg/dL (baseline 1.2 mg/dL). What is the most likely mechanism underlying this clinical deterioration?

  1. Voriconazole inhibition of CYP3A4, leading to increased tacrolimus concentrations. (correct answer)
  2. Direct nephrotoxicity from the voriconazole intravenous formulation's excipient.
  3. A synergistic pharmacodynamic effect between voriconazole and tacrolimus on renal tubules.
  4. An idiosyncratic reaction to voriconazole causing acute interstitial nephritis.
Explanation: This is a classic drug-drug interaction. Tacrolimus is a substrate of the CYP3A4 enzyme and has a narrow therapeutic index with significant nephrotoxicity and neurotoxicity at supratherapeutic levels. Voriconazole is a potent inhibitor of CYP3A4. When co-administered, voriconazole significantly reduces tacrolimus metabolism, leading to toxic accumulation. The patient's symptoms (tremor, headache) and acute kidney injury are hallmark signs of tacrolimus toxicity. This interaction necessitates a significant reduction in the tacrolimus dose and close therapeutic drug monitoring.

Question 20

A 70-year-old male with a history of Class III heart failure with a left ventricular ejection fraction of 30% is diagnosed with extensive onychomycosis. His physician is considering oral antifungal agents. Which of the following medications has a black box warning regarding its potential to cause or exacerbate congestive heart failure?

  1. Terbinafine
  2. Itraconazole (correct answer)
  3. Fluconazole
  4. Griseofulvin
Explanation: Itraconazole has demonstrated negative inotropic effects and has a black box warning stating it should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction, such as congestive heart failure (CHF), or a history of CHF. Terbinafine's main concern is hepatotoxicity. Fluconazole and griseofulvin are not associated with this specific cardiovascular risk.